94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Mol. Med
Sec. Molecular Medicine and Cancer Treatment
Volume 5 - 2025 | doi: 10.3389/fmmed.2025.1552323
This article is part of the Research Topic Current trends in Immunotherapy: From Monoclonal Antibodies to CAR-T Cells View all articles
Cell surface vimentin: a natural human immune response target for immunotherapy
Provisionally accepted- 1 University of California, San Diego, La Jolla, United States
- 2 Moores Cancer Center, School of Medicine, University of California, San Diego, La Jolla, California, United States
Natural human monoclonal antibodies obtained from sentinel lymph nodes of cancer patients identify cell surface vimentin. One of these vimentin-reactive antibodies, pritumumab, has been used to treat brain cancer patients. This review summarizes data on mAbs reactive with cell surface vimentin and their origin from lymph nodes of cancer patients.
Keywords: Vimentin, Pritumumab, Immunotherapy, antibody cocktails, Lymph Nodes, germinal centers
Received: 27 Dec 2024; Accepted: 10 Feb 2025.
Copyright: © 2025 Glassy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Mark Charles Glassy, University of California, San Diego, La Jolla, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.